Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04630444 · ClinicalTrials.gov registry record · Early Phase 1
Riluzole Effects on Hippocampus Biomarkers
A Early Phase 1 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT04630444 is a Early Phase 1 study that has completed, run by Mclean Hospital. The registered enrollment target is 20 participants.
The verdict
NCT04630444, a Early Phase 1 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
To examine the clinical efficacy of the anti-glutamatergic medication riluzole in posttraumatic stress disorder (PTSD), and its effect on hippocampus biomarkers that our laboratory previously has identified using MRS.
Interventions
- DRUG Riluzole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-03-16 |
| Est. Completion | 2019-03-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04630444
The ClinicalTrials.gov registry entry for NCT04630444 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Riluzole is the first listed.
NCT04630444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04630444 about?
NCT04630444 is a clinical study titled "Riluzole Effects on Hippocampus Biomarkers". To examine the clinical efficacy of the anti-glutamatergic medication riluzole in posttraumatic stress disorder (PTSD), and its effect on hippocampus biomarkers that our laboratory previously has identified using MRS.
What is the current status of trial NCT04630444?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2017-03-16. Estimated completion is 2019-03-16.
What interventions are being tested in trial NCT04630444?
The interventions under investigation include: Riluzole (DRUG).
Who is sponsoring clinical trial NCT04630444?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.